27/08/2007 (Agence Europe) - Further to the recall of the product from the EU market in June 2007, the European Commission suspended, on 7 August, the marketing authorisation for Roche's antiretroviral medicinal product, Viracept - an antiretroviral medicine used in combination with other antiviral medicines to treat adults, adolescents and children over 3 years of age who are infected with the human immunodeficiency virus, HIV-1. Suspension follows the contamination of certain batches of Viracept with ethyl mesilate, a genotoxic substance. The decision is based on scientific conclusions of the European Medicines Agency (EMEA), and follows consultation with Member States. The suspension can only be lifted by a further decision of the Commission, after an assessment by the Agency of new data. (ol)